PuSH - Publikationsserver des Helmholtz Zentrums München

Export: TXT Text RIS Endnote (RIS) BIB BibTeX
Götz, A. ; Jall, S. ; Tschöp, M.H. ; Müller, T.D.

Inkretinbasierte Medikamente zur Diabetes- und Adipositastherapie. Entwicklungsperspektiven.  

Incretin-based polyagonists for the treatment of diabetes and obesity: Recent advances.

Diabetologie 13, 505–513 (2017)
Postprint DOI
Open Access Green
Background: Along with the global increase in obesity, type 2 diabetes continues to spread worldwide. Thus, safe and effective treatment options are urgently needed because nonpharmacological treatment options, including lifestyle changes in diet and physical activity, fail to achieve sustained weight loss and glycemic control. Objectives: An overview of established therapeutic options in the treatment of obesity is presented with a focus on the discovery and translational relevance of new polyagonist-based therapies. Materials and methods: Recently published trials in the development and application of monomeric peptide-based polyagonists and peptide-based transport of steroid and thyroid hormones to treat obesity and diabetes are summarized and assessed. Results: Currently available pharmacological attempts to treat obesity have limited success with notable adverse effects. More promising are novel unimolecular hormonal polyagonists that have the unique potential to reverse obesity and diabetes in animal models. These activate up to three receptors with similar affinity. Beneficial effects on body weight and blood sugar levels in animals have been observed in preclinical research with a GLP-1/glucagon coagonist (GLP: glucagon-like peptide), a GLP-1/GIP coagonist (GIP: glucose-dependent insulinotropic polypeptide), and a GLP-1/GIP/glucagon triagonist. Similar positive effects could be demonstrated for steroid and thyroid hormones which are transported to specific tissues using a peptide transport molecule. Particularly promising are GLP-1/estrogen and glucagon/T3 (triiodothyronine). Conclusions: This article provides an overview of established therapeutic options in the treatment of obesity and focuses on the discovery and translational relevance of new polyagonist-based therapies.
Impact Factor
Scopus SNIP
Altmetric
0.072
0.086
Tags
Anmerkungen
Besondere Publikation
Auf Hompepage verbergern

Zusatzinfos bearbeiten
Eigene Tags bearbeiten
Privat
Eigene Anmerkung bearbeiten
Privat
Auf Publikationslisten für
Homepage nicht anzeigen
Als besondere Publikation
markieren
Publikationstyp Artikel: Journalartikel
Dokumenttyp Wissenschaftlicher Artikel
Schlagwörter Blood Glucose Regulation ; Body Weight ; Glucagon-like Peptide 1 ; Multihormone Treatment ; Pharmacology; Glucagon-like Peptide-1; Gastric-inhibitory Polypeptide; Corrects Obesity; Food-intake; Agonist; Rodents; Type-2; Mice; Estrogen; Receptor
Sprache deutsch
Veröffentlichungsjahr 2017
HGF-Berichtsjahr 2017
ISSN (print) / ISBN 2731-7447
e-ISSN 2731-7455
Zeitschrift Diabetologie, Die
Quellenangaben Band: 13, Heft: 7, Seiten: 505–513 Artikelnummer: , Supplement: ,
Verlag Springer
Verlagsort New York
Begutachtungsstatus Peer reviewed
Institut(e) Institute of Diabetes and Obesity (IDO)
Institute of Diabetes and Regeneration Research (IDR)
POF Topic(s) 90000 - German Center for Diabetes Research
30201 - Metabolic Health
Forschungsfeld(er) Helmholtz Diabetes Center
PSP-Element(e) G-501900-221
G-502200-001
G-502300-001
DOI 10.1007/s11428-017-0267-x
WOS ID WOS:000413822400010
Scopus ID 85030680079
Erfassungsdatum 2017-10-18
[➜Korrektur melden]